Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1213-1217

  Vénat Bouvet, Laurence ^a   Fermeaux, Veronique ^a   Leobon, Sophie ^a   Saidi, Nadira ^a   Monteil, Jacques ^a   Mollard, Joelle ^b   Aubard, Yves ^b   Jammet, Isabelle ^b   Tubiana Mathieu, Nicole ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b Mother and Child Hospital   (France)

Author keywords

Adjuvant chemotherapy; Molecular biomarkers; Node negative breast cancer; UPA PAI 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; NODE NEGATIVE BREAST CANCER; PROSPECTIVE STUDY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DECISION MAKING; FEMALE; FOLLOW UP; LYMPH NODE; METABOLISM; MIDDLE AGED; MOLECULAR BIOMARKERS; NODE-NEGATIVE BREAST CANCER; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; UPA-PAI-1; VERY ELDERLY;

ADJUVANT CHEMOTHERAPY; MOLECULAR BIOMARKERS; NODE-NEGATIVE BREAST CANCER; UPA-PAI-1;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84899704027     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tetu B, Trudel D and Wang CS: Proteases by reactive stromal cells in cancer: An attractive therapeutic target. Bull Cancer 93: 944-948, 2006 (in French).
2. Harbeck N, Kates R, Look M and Foekens J: On behalf of the pooled analysis study of the EORTC Receptor and Biomarker Group (RBG): Pooled analysis (n=8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 22(14S): 523, 2004.
3. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Janicke F, Schmitt M and Foekens JA: Pooled analysis of prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002.
4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr. and American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312, 2007.
5. Société française de sénologie et de pathologie mammaire (SFSPM) et Rapport 2009 sur l'état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1 ODTeM: Résumó des conclusions des deux rapports publiés en novembre 2009 dans le cadre du partenariat avec l'INCA. La lettre du Sénologue 46: 28-31, 2009 (in French).
6. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Janicke F and Klijn JG: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
7. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP and Foekens JA: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5: 348-352, 2004.
8. Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Hofler H, Janicke F, Graeff H and Schmitt M: Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 80: 419-426, 1999.
9. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M and German NSG: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93: 913-920, 2001.
10. Gnant M, Harbeck N and Thomssen C: St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 6: 136-141, 2011.
11. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ and Panel M: Thresholds for therapies: Highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329, 2009.
12. Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Janicke F, Kramer MD, Foekens JA, Brunner N, Brugal G, Pedersen AN and Benraad TJ: External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78: 1434-1441, 1998.
13. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993.
14. Harbeck N, Alt U, Berger U, Kruger A, Thomssen C, Janicke F, Hofler H, Kates RE and Schmitt M: Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7: 2757-2764, 2001.
15. Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Janicke F, Hofler H, Graeff H and Schmitt M: Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 18: 2187-2197, 1998.
16. Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C and Harbeck N: Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 FEC versus 3 FEC/3 docetaxel. BMC Cancer 11: 140, 2011.
17. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmuller S, Kiechle M, Janicke F, Thomssen C and Chemo NSG: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in nodenegative breast cancer patients. Eur J Cancer 49: 1825-1835, 2013.
18. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
19. Janicke F, Schmitt M and Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17: 303-312, 1991.
20. Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV and Sweep FC: Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph nodenegative breast carcinoma. Cancer 101: 486-494, 2004.
21. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Hofler H, Janicke F, Graeff H and Schmitt M: Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 54: 147-157, 1999.
22. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL and Klijn JG: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636-643, 2000.
23. Ferno M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801, 1996.
24. Cufer T, Borstnar S and Vrhovec I: Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 18: 106-115, 2003.
25. Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M and Namer M: Node negative breast cancer. Beyond international consensus: a pragmatic approach. Bull Cancer 98: 807-825, 2011 (in French).